NBRV News and Press, Nabriva Therapeutics plc From 12/07/20

- Amen ded agreement encompasses enhanced manufacturing collaboration and regulatory support -A ccelerates milestone payments to Nabriva , including fourth quarter 2020 payment of $1 million DUBLIN, Ireland, Dec. 07, 2020...

DUBLIN, Ireland, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will effect a 1-for-10 reverse st...

Nabriva Therapeutics plc (NBRV) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Gary Sender - Chief Financial Officer Ted Schroeder - Chief Executive Officer Steven Gelone - President and Chief Operating Officer Conference Call Participants Alan Carr - Needha...

The following slide deck was published by Nabriva Therapeutics plc in conjunction with their 2020 Q3 earnings call. For further details see: Nabriva Therapeutics plc 2020 Q3 - Results - Earnings Call Presentation

Nabriva Therapeutics (NBRV): Q3 GAAP EPS of -$0.09 in-line.Revenue of $1.29M (-81.4% Y/Y) beats by $0.84M.Shares +0.37%.Press Release For further details see: Nabriva Therapeutics EPS in-line, beats on revenue

-Relaunch of Xenleta ® and Sivextro ® commenced in late September- - Type A Meeting with FDA for Contepo™ held on October 30 th - -Conference call today at 4:30 p.m. Eastern Time- DUBLIN, Ireland, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Nabri...

DUBLIN, Ireland, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter fin...

-- Findings underscore potential of XENLETA as a first-in-class pleuromutilin antibiotic for the IV and oral treatment of CABP in adults, including older patients with comorbidities who are at risk of poor outcomes -- -- Pooled analysis of data by age group from pivotal LEAP 1 and LEA...

The following slide deck was published by Nabriva Therapeutics plc in conjunction with this Read more ...

Nabriva Therapeutics ( NBRV +6.7% )   announces that the Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for Xenleta (lefamulin) for injection when administered in the hospital inpatient setting. More news on: Nabriva Therapeut...